CD8A and melanoma: Pharmacological inhibitors of EZH2, including tazemetostat, have shown promise in preclinical melanoma models by restoring antigen presentation, enhancing CD8<sup>+</sup> T-cell infiltration, and reversing transcriptional programs associated with immune resistance.